ArticleAmerican journal of translational research2025
Quantitative dynamic contrast-enhanced MRI parameters effectively predict treatment efficacy of neoadjuvant chemotherapy in breast cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapy-induced tumor regression heterogeneity for early prediction of response and prognosis in HER2-positive breast cancer.BMC medical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the predictive value of quantitative DCE-MRI parameters for estimating the treatment efficacy of neoadjuvant chemotherapy (NACT) in breast carcinoma (BC).
methodsA retrospective analysis was conducted on 178 pathologically confirmed cases of BC, diagnosed via puncture biopsy, at The Second Affiliated Hospital of Anhui Medical University between January 2019 and June 2023. All patients received preoperative NACT. Based on postoperative pathological inspection results, 53 patients with grade IV-V pathological responses were included in the major histological response (MHR) group, and the remaining 125 with grade I-III pathological responses were assigned to the non-major histological response (NMHR) group. The pre- and post-chemotherapy early-phase enhancement rate (E
resultsThe MHR group showed statistically higher post-NACT D-max reduction rate and TVRR than the NMHR group. The two patient cohorts were similar in pre-chemotherapy K
conclusionsThe pre-NACT quantitative DCE-MRI parameters are not effective in predicting the therapeutic outcome of NACT. However, the post-NACT DCE-MRI parameters provide accurate and reliable predictions of pathological responses, with K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.